CR20130377A - Métodos y productos de fármaco para tratar enfermedad de alzheimer - Google Patents

Métodos y productos de fármaco para tratar enfermedad de alzheimer

Info

Publication number
CR20130377A
CR20130377A CR20130377A CR20130377A CR20130377A CR 20130377 A CR20130377 A CR 20130377A CR 20130377 A CR20130377 A CR 20130377A CR 20130377 A CR20130377 A CR 20130377A CR 20130377 A CR20130377 A CR 20130377A
Authority
CR
Costa Rica
Prior art keywords
products
disease
treat alzheimer
drug methods
drug
Prior art date
Application number
CR20130377A
Other languages
English (en)
Inventor
Allen D Roses
Rajneesh Taneja
Original Assignee
Zinfandel Pharmaceuticals Inc
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=46491234&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CR20130377(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zinfandel Pharmaceuticals Inc, Takeda Pharmaceutical filed Critical Zinfandel Pharmaceuticals Inc
Publication of CR20130377A publication Critical patent/CR20130377A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/118—Prognosis of disease development
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/172—Haplotypes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Pathology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

se proporcionan productos de fármaco con pioglitazona de baja dosis para utilizarse en el tratamiento (por ejemplo, retraso de desarrollo) daño cognitivo del tipo de alzheimer.-
CR20130377A 2011-01-10 2013-08-05 Métodos y productos de fármaco para tratar enfermedad de alzheimer CR20130377A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161431370P 2011-01-10 2011-01-10

Publications (1)

Publication Number Publication Date
CR20130377A true CR20130377A (es) 2013-09-20

Family

ID=46491234

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20130377A CR20130377A (es) 2011-01-10 2013-08-05 Métodos y productos de fármaco para tratar enfermedad de alzheimer

Country Status (27)

Country Link
US (4) US9102666B2 (es)
EP (2) EP2665479B1 (es)
JP (4) JP2014505055A (es)
KR (2) KR20180050420A (es)
CN (2) CN103501783A (es)
AR (1) AR084816A1 (es)
AU (1) AU2012205798B2 (es)
BR (1) BR112013017446A2 (es)
CA (1) CA2824050A1 (es)
CL (1) CL2013001947A1 (es)
CO (1) CO6741212A2 (es)
CR (1) CR20130377A (es)
DO (1) DOP2017000105A (es)
EA (2) EA201691399A1 (es)
EC (1) ECSP13012814A (es)
GE (1) GEP201706786B (es)
HK (1) HK1246660A1 (es)
IL (2) IL226975B (es)
MA (1) MA34828B1 (es)
MX (2) MX339844B (es)
PE (2) PE20181179A1 (es)
SG (1) SG191399A1 (es)
TN (1) TN2013000256A1 (es)
TW (3) TWI645853B (es)
UA (1) UA114704C2 (es)
UY (1) UY33863A (es)
WO (1) WO2012096873A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8846315B2 (en) * 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
JP5833922B2 (ja) * 2008-08-12 2015-12-16 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
EP2665479B1 (en) * 2011-01-10 2019-06-26 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease
CA2852417A1 (en) 2011-10-21 2013-04-25 Takeda Pharmaceutical Company Limited Sustained-release preparation
JP2015505314A (ja) * 2012-01-09 2015-02-19 武田薬品工業株式会社 アルツハイマー病を治療する方法及び医薬品
WO2014171542A1 (ja) * 2013-04-19 2014-10-23 武田薬品工業株式会社 放出制御製剤
JP6364488B2 (ja) * 2013-11-26 2018-07-25 ユニバーシティー オブ ノース テキサス ヘルス サイエンス センター アット フォートワースＵｎｉｖｅｒｓｉｔｙ Ｏｆ Ｎｏｒｔｈ Ｔｅｘａｓ Ｈｅａｌｔｈ Ｓｃｉｅｎｃｅ Ｃｅｎｔｅｒ Ａｔ Ｆｏｒｔ Ｗｏｒｔｈ 認知欠損を治療するための個別化医療的手法
JP6566471B2 (ja) * 2015-07-01 2019-08-28 国立大学法人福井大学 自閉スペクトラム症診断補助のための医療用画像処理方法及び医療用画像処理システム並びにバイオマーカー
WO2017015543A1 (en) 2015-07-23 2017-01-26 Asuragen, Inc. Methods, compositions, kits, and uses for analysis of nucleic acids comprising repeating a/t-rich segments
US20200095280A1 (en) * 2016-12-23 2020-03-26 Genervon Biopharmaceuticals Llc Methods of using GM6 in diagnosing and treating Alzheimers disease
JP6161183B1 (ja) 2017-02-14 2017-07-12 株式会社日本生物製剤 記憶改善用ペプチド
CA3037958C (en) * 2017-02-22 2022-06-14 Jeffrey L. Sugarman Glitazones for topical application
WO2019086555A1 (en) * 2017-10-31 2019-05-09 Ge Healthcare Limited Medical system for diagnosing cognitive disease pathology and/or outcome
US10888225B2 (en) * 2017-11-10 2021-01-12 Weinberg Medical Physics Inc Red blood cells as voltage-sensitive contrast agents
JP7152520B2 (ja) * 2018-05-25 2022-10-12 トヨタ モーター ヨーロッパ 人間の脳の知覚負荷及び刺激知覚のレベルを決定するシステム及び方法
WO2019234664A1 (en) 2018-06-06 2019-12-12 Minoryx Therapeutics S.L. 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases
CN110779566B (zh) * 2018-07-13 2021-09-28 致伸科技股份有限公司 具有辅助判断功能的产品测试***及产品测试辅助方法
US20220211700A1 (en) * 2019-05-23 2022-07-07 Indiana University Research And Technology Corporation Methods for Objective Assessment of Memory, Early Detection of Risk for Alzheimer's Disease, Matching Individuals With Treatments, Monitoring Response to Treatment, and New Methods of Use for Drugs
US10902351B1 (en) * 2019-08-05 2021-01-26 Kpn Innovations, Llc Methods and systems for using artificial intelligence to analyze user activity data
CN112151113A (zh) * 2020-09-27 2020-12-29 类承斌 一种迟发性阿尔茨海默症关联基因变异的早期筛查方法
CN114452264B (zh) * 2021-12-15 2023-09-05 东药集团沈阳施德药业有限公司 一种盐酸吡格列酮胶囊及其制备方法
KR20230134755A (ko) 2022-03-15 2023-09-22 사회복지법인 삼성생명공익재단 유럽 인구 데이터 기반 알츠하이머병 치매의 발병 위험군 또는 조기 증상 발현 위험군, 기억상실형 경도인지장애의 발병 위험군 및/또는 아밀로이드β 침착에 대한 PET 양성 위험군을 예측하기 위한 정보를 제공하는 방법
TWI822460B (zh) * 2022-11-11 2023-11-11 國立陽明交通大學 罹患阿茲海默症之風險分析方法

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2507631A (en) 1944-01-19 1950-05-16 Ciba Pharm Prod Inc Pyridine and piperidine compounds and process of making same
AR240698A1 (es) 1985-01-19 1990-09-28 Takeda Chemical Industries Ltd Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
US6060237A (en) 1985-02-26 2000-05-09 Biostar, Inc. Devices and methods for optical detection of nucleic acid hybridization
US5112460A (en) 1986-10-21 1992-05-12 Northeastern University High performance microcapillary gel electrophoresis
SG59988A1 (en) 1987-09-04 1999-02-22 Beecham Group Plc Substituted thiazolidinedione derivatives
US5595883A (en) 1990-06-01 1997-01-21 E. R. Squibb & Sons, Inc. Method of diagnosing alzheimer's disease by measuring acetylcholinesterase activity in ocular fluid
US5171750A (en) 1991-09-26 1992-12-15 The United States Of America As Represented By The Department Of Health And Human Services Substituted phenserines as specific inhibitors of acetylcholinesterase
TW263504B (es) 1991-10-03 1995-11-21 Pfizer
US5326770A (en) 1992-07-17 1994-07-05 The Du Pont Merck Pharmaceutical Company Monoamine oxidase-B (MAO-B) inhibitory 5-substituted 2,4-thiazolidinediones useful in treating memory disorders of mammals
ZA936492B (en) 1992-09-10 1995-03-02 Lilly Co Eli Compounds useful as hypoglycemic agents and for treating Alzheimer's disease.
ES2148116T1 (es) 1992-10-13 2000-10-16 Univ Duke Metodos de detectar la enfermedad de alzheimer.
TWI238064B (en) 1995-06-20 2005-08-21 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
ES2100129B1 (es) 1995-10-11 1998-02-16 Medichem Sa Nuevos compuestos aminopiridinicos policiclicos inhibidores de acetilcolinesterasa, procedimiento para su preparacion y su utilizacion.
JPH09176162A (ja) 1995-12-22 1997-07-08 Toubishi Yakuhin Kogyo Kk チアゾリジンジオン誘導体及びその製造法並びにそれを含む医薬組成物
US5904824A (en) 1997-03-07 1999-05-18 Beckman Instruments, Inc. Microfluidic electrophoresis device
EP1006794B1 (en) 1997-03-12 2007-11-28 Robert W. Esmond A method for treating or preventing alzheimer's disease
DE69809827D1 (de) 1997-03-31 2003-01-16 Korea Res Inst Chem Tech Chinolinische Sulfid-Derivate als NMDA Rezeptor-Antagonisten und Verfahren zu ihrer Herstellung
CA2311125C (en) 1997-11-19 2011-01-18 Takeda Chemical Industries, Ltd. Apoptosis inhibitor
US7122373B1 (en) 1998-05-14 2006-10-17 Nuvelo, Inc. Human genes and gene expression products V
US6964868B1 (en) 1998-01-28 2005-11-15 Nuvelo, Inc. Human genes and gene expression products II
CA2348609A1 (en) 1998-11-10 2000-05-18 Genset S.A. Methods, software and apparati for identifying genomic regions harboring a gene associated with a detectable trait
US6191154B1 (en) 1998-11-27 2001-02-20 Case Western Reserve University Compositions and methods for the treatment of Alzheimer's disease, central nervous system injury, and inflammatory diseases
CN1078616C (zh) 1998-12-16 2002-01-30 中国科学院上海生命科学研究中心 一种检测样品中是否存在老年痴呆病基因的方法和试剂盒
JP2000273040A (ja) 1999-01-19 2000-10-03 Sankyo Co Ltd トログリタゾンを含有するアポトーシス抑制剤
US6401043B1 (en) 1999-04-26 2002-06-04 Variagenics, Inc. Variance scanning method for identifying gene sequence variances
CA2371391A1 (en) 1999-04-29 2000-11-09 City Of Hope Pentoxifylline, pioglitazone and metformin are inhibitors of formation of advanced glycation endproducts (age's)
DE19936719A1 (de) 1999-08-06 2001-02-15 Gruenenthal Gmbh Substituierte 1,5-Dihydropyrrol-2-on-Derivate
US6559188B1 (en) 1999-09-17 2003-05-06 Novartis Ag Method of treating metabolic disorders especially diabetes, or a disease or condition associated with diabetes
AU7995300A (en) * 1999-10-05 2001-05-10 Bethesda Pharmaceuticals, Inc. Dithiolane derivatives
AR030920A1 (es) 1999-11-16 2003-09-03 Smithkline Beecham Plc Composiciones farmaceuticas para el tratamiento de la diabetes mellitus y condiciones asociadas con la diabetes mellitus, y procedimientos para preparar dichas composiciones
US6532467B1 (en) 2000-04-10 2003-03-11 Sas Institute Inc. Method for selecting node variables in a binary decision tree structure
US6432985B2 (en) 2000-04-25 2002-08-13 Hoffmann-La Roche Inc. Neuroprotective substituted piperidine compounds with activity as NMDA NR2B subtype selective antagonists
AU2002213136B2 (en) 2000-10-11 2007-01-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
CN101426763A (zh) 2000-10-11 2009-05-06 埃斯佩里安医疗公司 用于胆固醇治疗和相关应用的硫化物和二硫化物化合物和组合物
US20040122091A1 (en) 2000-10-11 2004-06-24 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US6673780B2 (en) 2000-10-11 2004-01-06 Esperion Therapeutics, Inc. Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US7304093B2 (en) 2000-10-11 2007-12-04 Esperion Therapeutics, Inc. Ketone compounds and compositions for cholesterol management and related uses
US6838452B2 (en) 2000-11-24 2005-01-04 Vascular Biogenics Ltd. Methods employing and compositions containing defined oxidized phospholipids for prevention and treatment of atherosclerosis
KR100865142B1 (ko) 2000-11-24 2008-10-24 바스큘라 바이오제닉스 리미티드 죽상 경화증의 예방 및 치료를 위해 정의된 산화 인지질을사용하는 방법 및 이를 함유하는 조성물
US6495335B2 (en) 2000-12-07 2002-12-17 Mario Chojkier Compositions and methods for diagnosing alzheimer's disease
DE10132725A1 (de) 2001-07-05 2006-08-03 Grünenthal GmbH Substituierte γ-Lactonverbindungen
US6680299B2 (en) 2001-07-27 2004-01-20 Enanta Pharmaceuticals, Inc. 4'-substituted leucomycins
US20040204502A1 (en) 2001-10-11 2004-10-14 Dasseux Jean-Louis Henri Sulfoxide and bis-sulfoxide compounds and compositions for cholesterol management and related uses
US20050020694A1 (en) 2001-10-11 2005-01-27 Dasseux Jean-Louis Henri Sulfide and disulfide compounds and compositions for cholesterol management and related uses
US6828462B2 (en) 2001-11-07 2004-12-07 Merz Pharma Gmbh & Co. Kgaa Unsaturated 1-amino-alkylcyclohexane NMDA, 5HT3, and neuronal nicotinic receptor antagonists
US7132244B2 (en) 2001-11-21 2006-11-07 Syn X Pharma, Inc. Betaine/GABA transport protein biopolymer marker indicative of insulin resistance
US7135297B2 (en) 2001-11-23 2006-11-14 Nanogen Inc. Protein biopolymer markers indicative of insulin resistance
US7052849B2 (en) 2001-11-23 2006-05-30 Syn X Pharma, Inc. Protein biopolymer markers predictive of insulin resistance
US20030220374A1 (en) 2002-01-14 2003-11-27 Pharmacia Corporation Compositions and methods of treatment involving peroxisome proliferator-activated receptor-gamma agonists and cyclooxygenase-2 selective inhibitors
WO2004005510A1 (ja) 2002-07-05 2004-01-15 Shionogi & Co., Ltd. 新規Nogo受容体様ポリペプチドおよびそのＤＮＡ
US20040265849A1 (en) 2002-11-22 2004-12-30 Applera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
CN1753662A (zh) 2002-12-24 2006-03-29 神经化学（国际）有限公司 用于治疗β－淀粉状蛋白相关疾病的治疗制剂
US20060135403A1 (en) 2002-12-24 2006-06-22 Francine Gervais Therapeutic formulations for the treatment of beta-amyloid related diseases
JP2006519440A (ja) 2003-02-14 2006-08-24 インタージェネティックス インコーポレイテッド 疾患の増大リスクの統計学的同定法
US7141669B2 (en) * 2003-04-23 2006-11-28 Pfizer Inc. Cannabiniod receptor ligands and uses thereof
US20050004179A1 (en) 2003-05-22 2005-01-06 Pedersen Ward A. Methods and materials for treating, detecting, and reducing the risk of developing Alzheimer's Disease
US20070203083A1 (en) 2003-06-13 2007-08-30 Mootha Vamsi K Methods Of Regulating Metabolism And Mitochondrial Function
EP1674452A4 (en) 2003-09-19 2007-10-10 Chugai Pharmaceutical Co Ltd NOVEL 4-PHENYLAMINO-BENZALDOXIME DERIVATIVE AND ITS USE AS MEK INHIBITOR
US7944467B2 (en) 2003-12-01 2011-05-17 Omnivision Technologies, Inc. Task-based imaging systems
US20050277129A1 (en) 2004-01-22 2005-12-15 Genaissance Pharmaceuticals APOE genetic markers associated with age of onset of Alzheimer's disease
TW200538738A (en) 2004-02-20 2005-12-01 Univ California Molecular flux rates through critical pathways measured by stable isotope labeling in vivo, as biomarkers of drug action and disease activity
WO2006054297A2 (en) 2004-11-17 2006-05-26 Compugen Ltd. Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis
US7833513B2 (en) 2004-12-03 2010-11-16 Rhode Island Hospital Treatment of Alzheimer's Disease
WO2006083854A2 (en) 2005-01-31 2006-08-10 Perlegen Sciences, Inc. Genetic basis of alzheimer's disease and diagnosis and treatment thereof
CA2620333A1 (en) 2005-08-26 2007-03-01 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
US20080262047A1 (en) * 2005-09-22 2008-10-23 Allen D Roses Ppar-Gamma Agonists for Improvement of Cognitive Function in Apoe4 Negative Patients
US7608412B2 (en) 2005-10-05 2009-10-27 Auburn University P62 as a diagnostic tool for alzheimer's disease
MX2008011871A (es) 2006-03-16 2009-02-10 Metabolic Solutions Dev Compan Analogos de tiazolidindiona para el tratamiento de enfermedad mediada por inflamacion metabolica.
US20080045582A1 (en) 2006-05-15 2008-02-21 Issam Zineh ENA-78 Gene Polymorphisms and Protein Concentrations as Diagnostic and Prognostic Tools
EP2037948B1 (en) 2006-05-30 2016-04-13 Mayo Foundation For Medical Education And Research Detecting and treating dementia
US7651840B2 (en) 2006-07-14 2010-01-26 Celera Corporation Genetic polymorphisms associated with Alzheimer's disease, methods of detection and uses thereof
EP2066355A2 (en) * 2006-09-19 2009-06-10 Braincells, Inc. Combination comprising a peroxisome proliferator activated receptor agent and a second neurogenic agent for treating a nervous system disorder, increasing neurodifferentiation and increasing neurogenesis
US20090042849A1 (en) 2006-12-06 2009-02-12 Yochai Birnbaum Phosphorylation of 5-lipoxygenase at ser523 and uses thereof
US7794937B2 (en) 2006-12-22 2010-09-14 Quest Diagnostics Investments Incorporated Cystic fibrosis transmembrane conductance regulator gene mutations
GB0702537D0 (en) 2007-02-12 2007-03-21 Leuven K U Res & Dev Treatment for excessive adiposity
US20080286876A1 (en) 2007-05-14 2008-11-20 Chissoe Stephanie GENES ASSOCIATED WITH ALZHEIMER'S DISEASE - Hltdip
WO2008147562A2 (en) 2007-05-25 2008-12-04 Childrens's Medical Center Corporation Dietary formulations and methods for treatment of inflammation and other disorders
TW200914006A (en) 2007-07-12 2009-04-01 Takeda Pharmaceutical Coated preparation
US8846315B2 (en) 2008-08-12 2014-09-30 Zinfandel Pharmaceuticals, Inc. Disease risk factors and methods of use
JP5833922B2 (ja) 2008-08-12 2015-12-16 ジンファンデル ファーマシューティカルズ インコーポレイテッド 疾患危険因子を同定する方法
US20100092470A1 (en) 2008-09-22 2010-04-15 Icb International, Inc. Antibodies, analogs and uses thereof
US20100136584A1 (en) 2008-09-22 2010-06-03 Icb International, Inc. Methods for using antibodies and analogs thereof
BRPI0919882A8 (pt) 2008-10-30 2017-09-19 Caris Life Sciences Luxembourg Holdings Métodos para avaliar padrões de rna
CN102301002A (zh) 2008-11-12 2011-12-28 卡里斯生命科学卢森堡控股有限责任公司 使用外来体来确定表现型的方法和***
WO2010066901A2 (en) 2008-12-12 2010-06-17 Poxel Tetrahydrotriazine compounds for treating diseases associated with ampk activity
KR101682489B1 (ko) 2009-02-02 2016-12-05 라일라 뉴트라슈티칼스 대사성 증후군의 조절을 위한 스파란터스 인디커스 및 가르시니아 망고스타나 유래의 조성물
JP5882196B2 (ja) 2009-04-23 2016-03-09 シーメンス・ヘルスケア・ダイアグノスティックス・インコーポレーテッドＳｉｅｍｅｎｓ Ｈｅａｌｔｈｃａｒｅ Ｄｉａｇｎｏｓｔｉｃｓ Ｉｎｃ． アディポネクチン受容体フラグメントの単量体及び二量体形態ならびに使用の方法
AU2010202926B2 (en) 2009-09-11 2016-07-14 Electrophoretics Limited Markers and methods relating to the assessment of Alzheimer's disease
US20110195403A1 (en) 2010-02-10 2011-08-11 Selinfreund Richard H Systems and methods for fertility analysis
JP5808349B2 (ja) 2010-03-01 2015-11-10 カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー セラノーシスのためのバイオマーカー
US9469876B2 (en) 2010-04-06 2016-10-18 Caris Life Sciences Switzerland Holdings Gmbh Circulating biomarkers for metastatic prostate cancer
EP2665479B1 (en) * 2011-01-10 2019-06-26 Zinfandel Pharmaceuticals, Inc. Methods and drug products for treating alzheimer's disease

Also Published As

Publication number Publication date
CO6741212A2 (es) 2013-08-30
TWI645853B (zh) 2019-01-01
BR112013017446A2 (pt) 2017-07-04
PE20181179A1 (es) 2018-07-20
UA114704C2 (uk) 2017-07-25
EP2665479B1 (en) 2019-06-26
US11179375B2 (en) 2021-11-23
TW201309293A (zh) 2013-03-01
GEP201706786B (en) 2017-12-11
MX2013008067A (es) 2013-08-09
KR20140041414A (ko) 2014-04-04
WO2012096873A1 (en) 2012-07-19
KR20180050420A (ko) 2018-05-14
KR102171747B1 (ko) 2020-11-04
JP2018196391A (ja) 2018-12-13
JP2020176142A (ja) 2020-10-29
JP2014505055A (ja) 2014-02-27
ECSP13012814A (es) 2014-02-28
AU2012205798A1 (en) 2013-05-02
WO2012096873A9 (en) 2013-09-12
EA201391017A1 (ru) 2014-04-30
CN103501783A (zh) 2014-01-08
US9724339B2 (en) 2017-08-08
PE20140051A1 (es) 2014-02-04
EA201691399A1 (ru) 2016-10-31
US9102666B2 (en) 2015-08-11
MX339844B (es) 2016-06-13
IL226975B (en) 2019-05-30
US20190151298A1 (en) 2019-05-23
TW201735922A (zh) 2017-10-16
TWI595875B (zh) 2017-08-21
US20170319565A1 (en) 2017-11-09
EP2665479A4 (en) 2014-06-18
EP3106165A1 (en) 2016-12-21
EP3106165B1 (en) 2019-02-27
HK1246660A1 (zh) 2018-09-14
TW201638337A (zh) 2016-11-01
SG191399A1 (en) 2013-08-30
CA2824050A1 (en) 2012-07-19
IL265155A (en) 2019-05-30
EP2665479A1 (en) 2013-11-27
US20160000769A1 (en) 2016-01-07
UY33863A (es) 2012-08-31
US20120184584A1 (en) 2012-07-19
MA34828B1 (fr) 2014-01-02
TWI612139B (zh) 2018-01-21
NZ611948A (en) 2015-08-28
JP2017014296A (ja) 2017-01-19
JP6745304B2 (ja) 2020-08-26
AU2012205798B2 (en) 2016-02-25
TN2013000256A1 (en) 2014-11-10
CN107362165A (zh) 2017-11-21
MX355479B (es) 2018-04-19
AR084816A1 (es) 2013-06-26
CL2013001947A1 (es) 2014-05-23
DOP2017000105A (es) 2017-05-31

Similar Documents

Publication Publication Date Title
CR20130377A (es) Métodos y productos de fármaco para tratar enfermedad de alzheimer
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
BR112013028665A2 (pt) compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
UA116648C2 (uk) Фумарати як проліки та їх застосування при лікуванні різних захворювань
CR20140108A (es) Compuesto de ciclopropanoamina
UY34750A (es) ?compuestos para el tratamiento del hiv, composiciones,métodos de preparación, intermediarios y métodos terapéuticos?.
EA201591166A1 (ru) Ингибиторы аутотаксина
MX2015016983A (es) Moduladores del transporte nuclear y usos de los mismos.
BR112014017673A8 (pt) Compostos de sulfonamida tricíclicos e métodos para fazer e usar os mesmos
ECSP14000606A (es) Agentes inductores de la apoptosis que pueden usarse para tratar el cáncer y las enfermedades inmunes y autoinmunes
UY34775A (es) Uso de laquinimod en alta dosis para el tratamiento de la esclerosis múltiple
GT201400288A (es) "compuestos de fenoxietil piperidina"
CO2017003321A2 (es) Inhibidores de gingipaina de lisina
MX2016000294A (es) Composicion farmaceutica para liberacion sostenida de lanreotida.
AR094851A1 (es) COMPUESTOS BICíCLICOS COMO AGONISTAS DE S1P₁
UY35328A (es) Tratamiento de formas progresivas de esclerosis múltiple con laquinimod
EA201591450A1 (ru) Фармацевтический состав, содержащий гликозаминогликан
UY35890A (es) Uso de laquinimod para retrasar la progresión de la enfermedad de huntington
AR094318A1 (es) Compuesto farmacéutico para la prevención y el tratamiento de un trastorno o enfermedad cognitivo, neurodegenerativo o neuronal
MX364528B (es) Witanólidos útiles para el tratamiento de enfermedades neurodegenerativas.
SV2017005441A (es) Antagonista de a2a de dosis baja para el tratamiento de tdah y la enfermedad de parkinson
MX2020006075A (es) Composiciones farmaceuticas de bendamustina.
BR112016016098A2 (pt) Compostos orgânicos
EA201892675A1 (ru) Фармацевтическая композиция, содержащая этеплирсен
UY34026A (es) ?terapia combinada oral para tratar infección por hcv en una subpoblación de pacientes específicos?.